ADC Therapeutics S.A. (ADCT) Stock Grade

About ADC Therapeutics S.A.'s fundamentals

ADC Therapeutics is a biotechnology company with a market capitalization of $160.3 million that achieved 14.9% year-over-year revenue growth in its latest period. However, the company operates at a significant loss, with a net margin of -175.3%, meaning it spent $1.75 for every dollar of revenue generated, and reported a net loss in its most recent annual statement. The company does not pay a dividend, which is typical for loss-making biotech firms reinvesting capital into research and development. The unusually high return on equity figure of 76.7% reflects the company's small equity base rather than profitable operations.